海正药业：子公司依维莫司原料药获欧洲药典适用性认证证书

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its wholly-owned subsidiary, Haizheng Hangzhou, received the Certificate of Suitability (CEP) for the active pharmaceutical ingredient Everolimus from the European Directorate for the Quality of Medicines (EDQM) [1] Group 1 - The receipt of the CEP certificate indicates that the Everolimus active pharmaceutical ingredient meets the quality standards set by the European regulatory authority [1] - This certification may enhance the company's marketability and competitiveness in the European pharmaceutical market [1] - The approval is expected to facilitate the company's expansion and strengthen its position in the global pharmaceutical industry [1]